New Procedure Offers Solution to Weight Rebound After GLP-1 Drug Discontinuation
A new clinical trial has introduced a minimally invasive procedure called duodenal mucosal resurfacing, which may help individuals maintain weight loss after discontinuing GLP-1 drugs. These drugs, including Ozempic, Wegovy, and Mounjaro, are widely used for diabetes management and weight loss, with many patients experiencing significant weight reduction. However, upon stopping these medications, a majority of patients tend to regain a substantial portion of the lost weight. The procedure involves using targeted heat to burn the unhealthy inner mucosal lining of the duodenum, stimulating the growth of new, healthy tissue. This process aims to reset the metabolism to the post-GLP-1 weight. Initial results from the trial, presented at Digestive Disease Week 2026, show promising outcomes, with participants maintaining over 80% of their weight loss six months after stopping the drug.